{"schema_version":"secwatch.filing_event.v1","accession":"0001438533-25-000002","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.632674+00:00","generated_at":"2026-05-28T03:05:37.426445+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Travere reports ~$74M preliminary Q4 net product sales; FILSPARI PSFs up 40% QoQ","bullets":["Preliminary Q4 2024 FILSPARI net sales ~$50M; total Q4 net product sales ~$74M; FY2024 ~$227M.","Received 693 new FILSPARI patient start forms in Q4, a 40% sequential increase in net sales vs Q3.","Cash, equivalents and marketable securities ~$371M at year-end 2024.","FDA accepted sNDA to modify liver monitoring for FILSPARI in IgAN; PDUFA date Aug 28, 2025.","On track for FSGS regulatory pathway update by Q4 2024 earnings call; partner CSL Vifor milestone $17.5M upon European full approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001438533-25-000002","json":"https://secwatch.observer/filing/0001438533-25-000002.json","markdown":"https://secwatch.observer/filing/0001438533-25-000002.md","text":"https://secwatch.observer/filing/0001438533-25-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000143853325000002/0001438533-25-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000143853325000002/tvtx-20250113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:05:37.426445+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}